期刊文献+

慢性乙型肝炎病毒感染对人肝细胞色素酶P4502C9的影响 被引量:1

Effects of chronic hepatitis B virus infection on human hepatic cytochrome P450 2C9
原文传递
导出
摘要 目的探讨慢性HBV感染对人肝细胞色素酶P450 2C9(CYP2C9)的影响。方法收集慢性HBV感染者和健康对照者的肝组织和血液标本各10份,聚合酶链反应-限制性片段长度多态性(PCR—RFLP)检测CYP2C9基因型,高效液相色谱(HPLC)检测肝组织样本中CYP2C9酶活性。RT—PCR和Western印迹法测定肝组织样本中CYP2C9 mRNA和蛋白表达的差异,数据行t检验。结果20份样本均为野生型CYP2C9(*1*1),未检测到突变型基因。反映酶活力的指标最大反应速度(Vmax)在慢性HBV感染组为(40.4±10.4)pmol·mg^-1·min^-1,健康对照组为(52.6±13.4)pmol·mg^-1·min^-1(t=2.269,P=0.0367);而酶特征性常数米氏常数(Km)分别为(263.5±66.4)μmol/L和(284.6±85.9)μmol/L(t=0.614,P=0.5471)。慢性HBV感染组和健康对照组CYP2C9 mRNA相对表达量分别为0.39±0.28和0.65±0.13(t=2.628,P=0.0171);蛋白相对表达量分别为0.26±0.13和0.60±0.19(t=4.688,P=0.0002)。结论慢性HBV感染在mRNA和蛋白水平降低肝脏CYP2C9酶的表达,导致酶活性下降。 Objective To investigate the effects of chronic hepatitis B virus (HBV) infection on human hepatic cytochrome P450 2C9 (CYP2C9). Methods Liver tissue samples and blood samples were obtained from 10 patients with chronic HBV infection and 10 healthy controls. CYP2C9 genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The activity of CYP2C9 was detected utilizing high performance liquid chromatography (HPLC). The expressions of CYP2C9 mRNA and protein were determined by reverse transcriptase-polymerase chain reaction (RT-PCR) and Western-blotting. The data were analyzed by t test. Results All the liver samples showed CYP2C9 wild-type ( * 1* 1), while CYP2C9 ( * 2) and CYP2C9 ( * 3) were not detected. The maximum velocity (Vmax) of CYP2C9 in patients with chronic HBV infection was (40.4±10.4) pmol·mg^-1·min^-1 and that of healthy controls was (52.6±13.4) pmol·mg^-1·min^-1(t=2. 269, P=0.036 7). The enzyme specific Km values of chronic HBV infection and healthy controls were (263.5 ±66.4) μmol/L and (284. 6 ±85. 9) μmol/L, respectively (t=0. 614, P= 0. 547 1). The expression of CYP2C9 mRNA in patients with chronic HBV infection (0.39±0.28) was significantly lower than that of healthy controls (0.65±0.13) (t=2. 628, P = 0. 017 1). Accordingly, the protein expression in patients with chronic HBV infection (0.26±0. 13) was lower than that of healthy controls (0. 60±0. 19) (t=4.688, P=0.000 2). Conclusion The expressions of CYP2C9 mRNA and protein are decreased in chronic HBV infection which may down-regulate the enzyme activity.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2009年第2期94-98,共5页 Chinese Journal of Infectious Diseases
基金 国家自然科学基金资助项目(30571660)
关键词 肝炎 乙型 慢性 多态现象 遗传 基因型 代谢 细胞色素P450酶系统 Hepatitis B, chronic Polymorphism, genetic Genotype Metabolism Cytochrome P-450 enzyme system
  • 相关文献

参考文献13

  • 1Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9 * 3. Clin Pharmacol Ther, 2001, 70:391-394.
  • 2Kim JS, Nafziger AN, Gaedigk A, et al. Effects of oral vitamin K on S and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol, 2001, 41 : 715-722.
  • 3Daly AK, King BP. Pharmacogenetics of oral anticoagulants.Pharmacogenetics, 2003,13 : 247-252.
  • 4Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther, 2005,77: 1-16.
  • 5Zhiqiang G, Zhaohui D, Qinhuan W,et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol, 2004,38 (10 Suppl 3) :S175-S178.
  • 6Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol, 1998, 45:525-538.
  • 7Kirchheiner J, Meineke I, Mailer G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet, 2004,43 : 267-278.
  • 8Kimura S, Pastewka J, Gelboin HV, et al. cDNA and amino acid sequences of two members of the human P450 IIC gene subfamily. Nucleic Acids Res, 1987,15: 10053-10054.
  • 9Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996,6 : 341-349.
  • 10Peyvandi F, Spreafico M, Siboni SM, et aI. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther, 2004, 75 :198-203.

同被引文献20

  • 1李爽,胡卓汉,缪晓辉.慢性乙型肝炎病毒感染对人肝细胞色素酶 P450 3A4的影响[J].中华医学杂志,2006,86(38):2703-2706. 被引量:5
  • 2Home page of human cytochrome P450(CYP)alIeIe nomenclature committee[ EB/OL]. [ 2008-09-09 ]. http://www, imm. ki. se/CYPalleles.
  • 3Hong X, ZbangS,Mao G, etal. CYP2C9 * 3 allelic variant is associated with metabolism of irbesartan inChinese population. Eur J Clin Pharmacol, 2005, 61(9): 627-634.
  • 4Bae JW,Kim HK,Kim JH, et al. Allele and genotype frequencies of CYP2C'9 in a Korean population. Br J Clin Pharmacol, 2005, 60(4) : 418-422.
  • 5Imai J, Ieiri K, Mamira K, et al. Polymorphism of the cytochrome P450 (CYP)2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.Pharmacogenetics, 2000, 10(6): 85-89.
  • 6Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphi sins on drug therapies: pharmacogenetic, pharmaenepigenetic and clinical aspects, Phamment Therapeutics, 2007,116(3) :496-526.
  • 7Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 2001,29(3) :268-273.
  • 8Dai D,Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacal Exp Ther,2001,299(3) :825-831.
  • 9Sata F, Sapone A, Elizondo G, et al. CYP3A4 aUelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther, 2000,67 (1) :48-56.
  • 10Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A.5 haplotypes in a Japanese population. Hum Mutat,2004,23(1):100-108.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部